Document is current
Any future updates will be listed below
-
Authors
Tsiami, Foteini https://orcid.org/0009-0001-6070-0434
Lago, Chiara https://orcid.org/0000-0002-1317-7847
Pozza, Noemi
Piccioni, Federica https://orcid.org/0000-0003-1210-3210
Zhao, Xuesong https://orcid.org/0000-0003-3007-7124
Lülsberg, Fabienne
Root, David E. https://orcid.org/0000-0001-5122-861X
Tiberi, Luca https://orcid.org/0000-0002-5983-3782
Kool, Marcel https://orcid.org/0000-0002-6557-5468
Schittenhelm, Jens https://orcid.org/0000-0002-9168-6209
Bandopadhayay, Pratiti https://orcid.org/0000-0002-4175-4760
Segal, Rosalind A. https://orcid.org/0000-0001-9850-8432
Tabatabai, Ghazaleh https://orcid.org/0000-0002-3542-8782
Merk, Daniel J. https://orcid.org/0000-0003-2935-6919
-
Funding
Funding for this research was provided by:
Wilhelm Sander-Stiftung (2022.094.1)
German Research Foundation (EXC 2180-390900677)
Dana-Farber Pediatric Low-Grad Glioma Program
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 9 July 2024
First Online: 7 August 2024
Declarations
:
: Not applicable.
: Not applicable.
: Ghazaleh Tabatabai has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure), as a consultant (Bayer, Boehringer Ingelheim, CureVac), as steering committee member in non-interventional trials (Bayer, Novocure), as a speaker (Novocure, Servier), and financial compensation for all these activities was provided as institutional funding to the University Hospital Tübingen. David E. Root receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir), and is a director of Addgene, Inc.
